secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-05-26T12:03:22+00:00
Accession:  0001437749-26-018318
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex reports positive predictive biomarker data for Reqorsa in NSCLC at ASCO 2026
--------------------------------------------------------------------------------

- In NSCLC patients, Trop-2 H-score >100 and PTEN H-score <100 correlated with prolonged PFS (p=0.05, p=0.03).
- Data from 18 patients across Acclaim-1 (osimertinib), Acclaim-2 (pembrolizumab), and Acclaim-3 (atezolizumab) trials.
- High (3+) Trop-2 expression showed near-significant correlation with PFS (p=0.053); will be further investigated as biomarker.
- In SCLC patients, Trop-2 levels were universally low; no significant correlation with PFS observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926018318/0001437749-26-018318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926018318/gnpx20260515_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-018318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer